• Enlivex randomized 135 of a planned 182 patients in its Phase 2b Allocetra knee osteoarthritis trial; all received their first injection.
• The placebo-controlled study targets adults aged 64 and older with moderate-to-severe, age-related primary knee osteoarthritis.
• Enrollment remains active in the United States, Denmark and Poland, with six-month topline results expected by mid-2027.
• Previously reported Phase 1/2a results showed positive outcomes at three and six months, supporting FDA Regenerative Medicine Advanced Therapy designation in July 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280800PRIMZONEFULLFEED9854837) on October 28, 2026, and is solely responsible for the information contained therein.